Oncogene addiction as a foundational rationale for targeted anti-cancer therapy: promises and perils

被引:172
|
作者
Torti, Davide [1 ]
Trusolino, Livio [1 ]
机构
[1] Univ Turin, Sch Med, Mol Pharmacol Lab, Inst Canc Res & Treatment IRCC, Turin, Italy
关键词
DNA damage; drug development; oncogene addiction; targeted therapies; tyrosine kinases; CELL LUNG-CANCER; TYROSINE KINASE INHIBITORS; CHRONIC MYELOID-LEUKEMIA; SYNTHETIC LETHAL INTERACTION; ACUTE LYMPHOBLASTIC-LEUKEMIA; ANAPLASTIC LYMPHOMA KINASE; BCR-ABL; BREAST-CANCER; C-MYC; POLY(ADP-RIBOSE) POLYMERASE;
D O I
10.1002/emmm.201100176
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
A decade has elapsed since the concept of oncogene addiction was first proposed. It postulates that - despite the diverse array of genetic lesions typical of cancer - some tumours rely on one single dominant oncogene for growth and survival, so that inhibition of this specific oncogene is sufficient to halt the neoplastic phenotype. A large amount of evidence has proven the pervasive power of this notion, both in basic research and in therapeutic applications. However, in the face of such a considerable body of knowledge, the intimate molecular mechanisms mediating this phenomenon remain elusive. At the clinical level, successful translation of the oncogene addiction model into the rational and effective design of targeted therapeutics against individual oncoproteins still faces major obstacles, mainly due to the emergence of escape mechanisms and drug resistance. Here, we offer an overview of the relevant literature, encompassing both biological aspects and recent clinical insights. We discuss the key advantages and pitfalls of this concept and reconsider it as an illustrative principle to guide post-genomic cancer research and drug development.
引用
收藏
页码:623 / 636
页数:14
相关论文
共 50 条
  • [21] The promise and perils of 'targeted therapy' of advanced ovarian cancer
    Markman, Maurie
    ONCOLOGY, 2008, 74 (1-2) : 1 - 6
  • [22] Molecular biology of cancer-associated fibroblasts: Can these cells be targeted in anti-cancer therapy?
    Gonda, Tamas A.
    Varro, Andrea
    Wang, Timothy C.
    Tycko, Benjamin
    SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY, 2010, 21 (01) : 2 - 10
  • [23] Personalised cancer care: promises and challenges of targeted therapy
    Tu, Shi-Ming
    Bilen, Mehmet A.
    Tannir, Nizar M.
    JOURNAL OF THE ROYAL SOCIETY OF MEDICINE, 2016, 109 (03) : 98 - 105
  • [24] Targeted Silencing of Inhibitors of Apoptosis Proteins with siRNAs: A Potential Anti-cancer Strategy for Hepatocellular Carcinoma
    Li, Gang
    Chang, Hong
    Zhai, Yun-Peng
    Xu, Wei
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2013, 14 (09) : 4943 - 4952
  • [25] TRAIL as a target in anti-cancer therapy
    Wu, Gen Sheng
    CANCER LETTERS, 2009, 285 (01) : 1 - 5
  • [26] Targeted anti-cancer agents and risk of venous thromboembolism
    Verso, Melina
    Moik, Florian
    Graziani, Mara
    Cohen, Alexander T.
    HAEMATOLOGICA, 2024, 109 (12)
  • [27] Biological Rationale for Targeting MEK/ERK Pathways in Anti-Cancer Therapy and to Potentiate Tumour Responses to Radiation
    Marampon, Francesco
    Ciccarelli, Carmela
    Zani, Bianca Maria
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2019, 20 (10)
  • [28] New horizons in systemic anti-cancer therapy in older people
    Parry, J. L.
    Hall, P. S.
    Young, J.
    AGE AND AGEING, 2018, 47 (03) : 340 - 348
  • [29] Non-canonical activation of GLI transcription factors -: Implications for targeted anti-cancer therapy
    Lauth, Matthias
    Toftgard, Rune
    CELL CYCLE, 2007, 6 (20) : 2458 - 2463
  • [30] Structural regression modelling of peptide based drug delivery vectors for targeted anti-cancer therapy
    Christian, Yvonne
    Redkar, Amay Sanjay
    Kumar, Naveen
    Jancy, Shine Varghese
    Chandrasekharan, Aneesh
    Santhoshkumar, Thankayyan Retnabai
    Ramakrishnan, Vibin
    DRUG DELIVERY AND TRANSLATIONAL RESEARCH, 2025, 15 (04) : 1284 - 1298